Innovation Pharmaceuticals Inc (IPIX)

[olden_grumpini]

What caught my eye in the last 10-Q (filed Nov 14, 2023) was the following:

Through the date of this report, management has been unable to secure additional financing, and the ability of the Company to continue as a going concern is becoming increasingly unlikely.

This new wording appeared before the following events occurred:
-- Alfasignma S.p.A. terminated their license agreement
-- both independent directors resigned
-- the MA Superior Court issued a >$1.4 million judgment against IPIX
-- trading in IPIX stock was restricted to the Expert Market.

In the 5 months since the filing it's likely that all remaining cash has been spent on salaries and legal expenses. The only viable asset is the BeaMedical holding and this will likely be the source of funds to satisfy the Cummings judgment.

The brilacidin fungal data is interesting, but brilacidin is at the end of its patent life and is being used under license by IPIX. IPIX does not own brilacidin. The license agreement has a defined expiration (see post https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171595146).